Pyrazolidinedione derivatives and their use as PPAR-gamma inhibitors
AssigneeKing Faisal University
InventorsMichelyne Haroun, Christophe Tratrat
Life of this patent
Estimating the term…
Abstract
The pyrazolidinedione derivatives were found to possess blood glucose lowering properties. These compounds were designed as potential PPAR gamma inhibitors, an essential molecular target for clinically used antidiabetic drugs. Owing to their promising anti-hyperglycemic activity, these derivatives may find useful applications for the treatment and/or prevention of obesity, diabetes type II and I, hyperglycemia and other diseases where PPAR gamma is implicated such as cancer, atherosclerosis and hyperlipidemia.
Claims4
A method of inhibiting PPAR-gamma in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
- N-(6-chlorobenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl) phenoxy)acetamide (1);
- 2-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethyl) benzo[d]thiazol-2-yl)acetamide (2);
- 2-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethoxy) benzo[d]thiazol-2-yl)acetamide (3);
- N-(6-chloro-5-methylbenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (4);
- N-(6-chloro-5-ethylbenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (5);
- N-(6-chloro-7-methylbenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (6);
- N-(4-chloro-6-fluorobenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (7);
- N-(6-chlorobenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (8);
- 3-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethyl) benzo[d]thiazol-2-yl)propanamide (9);
- 3-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethoxy) benzo[d]thiazol-2-yl)propanamide (10);
- N-(6-chloro-5-methylbenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (11);
- N-(6-chloro-5-ethylbenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (12);
- N-(6-chloro-7-methylbenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (13);
- N-(4-chloro-6-fluorobenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (14);
- and a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof.
A method of treating a PPAR-mediated disease or condition in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
- N-(6-chlorobenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl) phenoxy)acetamide (1);
- 2-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethyl) benzo[d]thiazol-2-yl)acetamide (2);
- 2-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethoxy) benzo[d]thiazol-2-yl)acetamide (3);
- N-(6-chloro-5-methylbenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (4);
- N-(6-chloro-5-ethylbenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (5);
- N-(6-chloro-7-methylbenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (6);
- N-(4-chloro-6-fluorobenzo[d]thiazol-2-yl)-2-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)acetamide (7);
- N-(6-chlorobenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (8);
- 3-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethyl) benzo[d]thiazol-2-yl)propanamide (9);
- 3-(4-((3,5-dioxopyrazolidin-4-ylidene)methyl)phenoxy)-N-(6-(trifluoromethoxy) benzo[d]thiazol-2-yl)propanamide (10);
- N-(6-chloro-5-methylbenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (11);
- N-(6-chloro-5-ethylbenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (12);
- N-(6-chloro-7-methylbenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (13);
- N-(4-chloro-6-fluorobenzo[d]thiazol-2-yl)-3-(4-((3,5-dioxopyrazolidin-4-ylidene) methyl)phenoxy)propanamide (14);
- and a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof;
- wherein the PPAR-mediated disease or condition is selected from the group consisting of diabetes, obesity, hyperglycemia, metabolic syndrome, atherosclerosis, and hyperlipidemia.
Dependencies are inferred from the claim text.